Expression and significance of baculovirus apoptosis inhibitor protein 5 in ovarian serous carcinoma

WANG Qian; XU Jianhao; GU Tingting; GAN Wenjuan

doi:10.7619/jcmp.20221589

Journal of Clinical Medicine in Practice > 2022 > 26(15): 95-102. > DOI: 10.7619/jcmp.20221589

WANG Qian, XU Jianhao, GU Tingting, GAN Wenjuan. Expression and significance of baculovirus apoptosis inhibitor protein 5 in ovarian serous carcinoma[J]. Journal of Clinical Medicine in Practice, 2022, 26(15): 95-102. DOI: 10.7619/jcmp.20221589

Citation:

PDF (5047 KB)

Expression and significance of baculovirus apoptosis inhibitor protein 5 in ovarian serous carcinoma

1.
Medical College of Soochow University, Suzhou, Jiangsu, 215000
2.
Department of Pathology, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, Jiangsu, 215300
3.
Department of Pathology, Suzhou Dushu Lake Hospital Affiliated to Suzhou University, Suzhou, Jiangsu, 215000

More Information

Received Date: May 18, 2022
Available Online: August 22, 2022

Graphical Abstract

Abstract

Abstract

Objective
To investigate the possibility of baculovirus apoptosis inhibitor protein 5(BIRC5) as a clinical diagnostic and prognostic marker for ovarian serous carcinoma and its potential mechanism.
Methods
The GSE73638, GSE27651 and GSE14001 datasets were downloaded from the GEO database, and the differentially expressed genes (DEGs) were screened using the GEO2R online analysis tool. The protein-protein interaction (PPI) network was constructed using the String database, and key genes in the PPI network were analyzed using Cytoscape software. The relationship between key genes and prognosis was analyzed in the GEPIA database. Expressions of BIRC5, Ki-67 and TP53 proteins in cancer and adjacent tissues in 58 clinical cases[38 cases of high-grade serous ovarian cancer (HGSOC) and 20 cases of low-grade serous ovarian cancer (LGSOC)] were detected for correlation of BIRC5 expression with clinicopathological factors by immunohistochemical method.
Results
GO and KEGG enrichment analysis of overlapping DEGs showed that BIRC5 was a key gene in ovarian serous carcinoma. The results of GEPIA database analysis showed that BIRC5 gene was correlated with the overall survival of ovarian cancer patients, which indicated that the higher the expression of BIRC5 was, the longer the survival cycle of patients lasted. There was no significant difference in the positive expression rate of BIRC5 protein in para-cancer tissues of LGSOC patients(χ²=1.026, P=0.311). The positive expression rate of BIRC5 protein in cancer tissues of HGSOC patients was higher than that in adjacent tissues, the difference was statistically significant (χ²=44.333, P < 0.001). BIRC5, TP53 and Ki-67 proteins were highly expressed in HGSOC cancer tissues, but lowly expressed in LGSOC cancer tissues. BIRC5 protein expression was correlated with age, International Federation of Gynecology and Obstetrics (FIGO) stage, Ki-67 protein expression and pathological type (P < 0.05), but had no correlation with TP53 protein expression in patients with ovarian serous carcinoma (P>0.05). The overall survival rate of HGSOC patients was lower than that of LGSOC group, but the difference was not statistically significant (χ²=3.522, P=0.061).
Conclusion
BIRC5 is a key gene of ovarian serous cancer and can be used as a new index for clinical diagnosis and survival prognosis of the disease. BIRC5 is a pro-cancer gene, which may promote the occurrence and development of ovarian cancer by regulating the expression of Ki-67 rather than the signal pathway of TP53.
- ovarian cancer,
- baculovirus apoptosis inhibitor protein 5,
- Ki-67,
- TP53,
- survival,
- prognosis

FullText(HTML)

References (21)

References

[1]	KUROKI L, GUNTUPALLI S R. Treatment of epithelial ovarian cancer[J]. BMJ, 2020, 371: m3773.
[2]	RICKARD B P, CONRAD C, SORRIN A J, et al. Malignant ascites in ovarian cancer: cellular, acellular, and biophysical determinants of molecular characteristics and therapy response[J]. Cancers, 2021, 13(17): 4318. doi: 10.3390/cancers13174318
[3]	杨佳, 嵇梦颖, 李雨荆, 等. 卵巢交界性肿瘤的临床特征及危险因素分析[J]. 实用临床医药杂志, 2022, 26(4): 114-118. doi: 10.7619/jcmp.20213184
[4]	GOULDING E A, SIMCOCK B, MCLACHLAN J, et al. Low-grade serous ovarian carcinoma: a comprehensive literature review[J]. Aust N Z J Obstet Gynaecol, 2020, 60(1): 27-33. doi: 10.1111/ajo.13105
[5]	SUŠAC I, OZRETIC P, GREGORIC M, et al. Polymorphisms in survivin (BIRC5 gene) are associated with age of onset in breast cancer patients[J]. J Oncol, 2019, 2019: 3483192.
[6]	WHEATLEY S P, ALTIERI D C. Survivin at a glance[J]. J Cell Sci, 2019, 132(7): jcs223826. doi: 10.1242/jcs.223826
[7]	DAI J B, ZHU B, LIN W J, et al. Identification of prognostic significance of BIRC5 in breast cancer using integrative bioinformatics analysis[J]. Biosci Rep, 2020, 40(2): BSR20193678. doi: 10.1042/BSR20193678
[8]	CAO Y J, ZHU W K, CHEN W Q, et al. Prognostic value of BIRC5 in lung adenocarcinoma lacking EGFR, KRAS, and ALK mutations by integrated bioinformatics analysis[J]. Dis Markers, 2019, 2019: 5451290.
[9]	LIU S H, HONG Y, MARKOWIAK S, et al. BIRC5 is a target for molecular imaging and detection of human pancreatic cancer[J]. Cancer Lett, 2019, 457: 10-19. doi: 10.1016/j.canlet.2019.04.036
[10]	HINGORANI P, DICKMAN P, GARCIA-FILION P, et al. BIRC5 expression is a poor prognostic marker in Ewing sarcoma[J]. Pediatr Blood Cancer, 2013, 60(1): 35-40. doi: 10.1002/pbc.24290
[11]	XU L L, YU W P, XIAO H, et al. BIRC5 is a prognostic biomarker associated with tumor immune cell infiltration[J]. Sci Rep, 2021, 11(1): 390. doi: 10.1038/s41598-020-79736-7
[12]	BARRETT T, WILHITE S E, LEDOUX P, et al. NCBI GEO: archive for functional genomics data sets: update[J]. Nucleic Acids Res, 2013, 41(Database issue): D991-D995.
[13]	WANG Y, MA X L, WANG Y X, et al. Comparison of different scoring systems in the assessment of estrogen receptor status for predicting prognosis in endometrial cancer[J]. Int J Gynecol Pathol, 2019, 38(2): 111-118. doi: 10.1097/PGP.0000000000000490
[14]	LISIO M A, FU L L, GOYENECHE A, et al. High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints[J]. Int J Mol Sci, 2019, 20(4): 952. doi: 10.3390/ijms20040952
[15]	ZHANG J, XU X Y, CHEN Y F, et al. The abnormal expression of chromosomal region maintenance 1(CRM1)-survivin axis in ovarian cancer and its related mechanisms regulating proliferation and apoptosis of ovarian cancer cells[J]. Bioengineered, 2022, 13(1): 624-633. doi: 10.1080/21655979.2021.2012416
[16]	YIN S N, DU J, ZHANG J, et al. Identification of key genes and pathway for ovarian neoplasms using the OVDM1 cell line based on bioinformatics analysis[J]. Med Sci Monit, 2019, 25: 4305-4313. doi: 10.12659/MSM.915422
[17]	HE X Y, YANG K H, WANG H L, et al. Expression and clinical significance of survivin in ovarian cancer: a meta-analysis[J]. PLoS One, 2018, 13(5): e0194463.
[18]	OZRETIC P, TRNSKI D, MUSANI V, et al. Non-canonical hedgehog signaling activation in ovarian borderline tumors and ovarian carcinomas[J]. Int J Oncol, 2017, 51(6): 1869-1877.
[19]	WANG B J, LI X, ZHAO G N, et al. miR-203 inhibits ovarian tumor metastasis by targeting BIRC5 and attenuating the TGFβ pathway[J]. J Exp Clin Cancer Res, 2018, 37(1): 235.
[20]	MONDAL S K, BASAK B, BHATTACHARYA S, et al. Role of WT1, B-cell lymphoma 2, ki-67(Mib1), and Her2/neu as diagnostic and prognostic immunomarkers in ovarian serous and endometroid carcinoma[J]. J Cancer Res Ther, 2021, 17(1): 164-169.
[21]	SU D, NIE M, YUE J. The G199X and V157fs mutations in the TP53 gene promote malignancy in serous ovarian cancer: an analysis using whole-exome sequencing[J]. Ann Transl Med, 2021, 9(8): 710.

[1]	SUN Bo, ZHOU Fang, XUE Fumin, LI Xiaoqin. Expression and correlation analysis of serum soluble myeloidcell trigger receptor 1, interleukin-21, 25 (OH) vitamin D in children with inflammatory bowel disease[J]. Journal of Clinical Medicine in Practice, 2024, 28(14): 105-108, 113. DOI: 10.7619/jcmp.20230984
[2]	ZENG Dong, SUN Wenwen, CHEN Guanghui, WANG Zhenzhen. Value of combined detection of cerebrospinal fluid lactate, interleukin-27 and interferon-γ in diagnosing bacterial meningitis after neurosurgical operation[J]. Journal of Clinical Medicine in Practice, 2024, 28(2): 23-27. DOI: 10.7619/jcmp.20232483
[3]	REN Lili, WANG Wenjuan, Gulinazaer·AIBIBULA, Gulixian·MAHEMUTI. Expression levels and significance of serum T lymphocyte subsets and cytokines in patients with different inflammatory phenotypes of bronchial asthma[J]. Journal of Clinical Medicine in Practice, 2022, 26(22): 33-37. DOI: 10.7619/jcmp.20221392
[4]	LIU Xilong, RONG Qian, XING Yue, PAN Biqiong, LU Dan. Research progress on relationship between interleukin-1 family and preeclampsia[J]. Journal of Clinical Medicine in Practice, 2022, 26(9): 107-111. DOI: 10.7619/jcmp.20214492
[5]	SONG Zhenzhen, CHEN Li, CAO Xiaowan, ZHANG Guoying. Progress of interleukin-33 in myocyte-related inflammatory diseases[J]. Journal of Clinical Medicine in Practice, 2021, 25(10): 124-127, 132. DOI: 10.7619/jcmp.20211008
[6]	CHANG Binglin, ZHANG Hao. Effect of propofol combined with oxycodone on inflammatory reactions and stress reactions in patients with acute craniocerebral injury[J]. Journal of Clinical Medicine in Practice, 2021, 25(2): 25-27,31. DOI: 10.7619/jcmp.20200572
[7]	JIN Yunzhou, LI Mingfang, ZHENG Sheng, ZHANG Jiqin, QU Yunfei, ZHANG Jianrong. Changes of lymphocyte,interleukin-6 and inflammatory indexes in patients with coronavirus disease 2019 under different conditions of disease[J]. Journal of Clinical Medicine in Practice, 2020, 24(6): 1-4. DOI: 10.7619/jcmp.202006001
[8]	DENG Lan. Study on the relationship between serum HBeAg levels and liver inflammation activity and fibrosis grading in patients with CHB[J]. Journal of Clinical Medicine in Practice, 2016, (17): 63-66. DOI: 10.7619/jcmp.201617020
[9]	GU Zhihong. Effect of intravenous immunoglobulin on inflammatory reaction and oxidative stress reaction of children with Kawasaki disease[J]. Journal of Clinical Medicine in Practice, 2016, (5): 103-106. DOI: 10.7619/jcmp.201605031
[10]	LI Shuping, JIANG Xuelian. Clinical correlation between inflammatory reaction and progress of eclampsism[J]. Journal of Clinical Medicine in Practice, 2014, (7): 147-148,151. DOI: 10.7619/jcmp.201407052

Cited By

Cited by

Periodical cited type(2)

1.	孙素红，周晓玲，李泽鹏，覃杏幸，孙东琪，磨奕玲，黄华萍. 柴胡当归散加减联合穴位注射丹参注射液治疗乙肝肝纤维化临床观察. 陕西中医. 2024(04): 477-480+489 .
2.	徐宇萱，牛建海，高欢. 龙胆泻肝汤加减对慢性乙型肝炎低病毒血症期抗纤维化改善、病毒载量及血清HBsAg、ADA的影响. 天津中医药. 2024(11): 1368-1372 .

Other cited types(1)

Get Citation

PDF

XML

Article views (162) PDF downloads (9) Cited by(3)

Turn off MathJax

Article Contents

Abstract

References

Expression and significance of baculovirus apoptosis inhibitor protein 5 in ovarian serous carcinoma